Dextromethorphan and guaifenesin use needs to be monitored meticulously in clients with "bad metabolizer" CYP2D6 enzyme stages and individuals who are sedated. This mix medication contains a massive median toxic dose (TD50) to median successful dose (ED50) ratio (or therapeutic index) in these clients. et al. The influence of CYP2D6 https://chemicalglobe.com/